JNJ Dividend Streak Tops Six Decades Amid Healthcare Momentum
Johnson & Johnson (NYSE:JNJ), a diversified healthcare group, has extended its uninterrupted dividend-growth streak for over six decades. This remarkable feat places it among an elite club of 'dividend kings' in American markets.
The company's momentum in oncology and immunology franchises is driving its growth, particularly with multiple myeloma and other blood-cancer treatments expanding their reach. Immunology therapies used for inflammatory conditions are also climbing as newer medicines take share from older options.
Johnson & Johnson's two-sided structure, consisting of innovative-medicine and medical-technology arms, smooths the bumps created by single product lines. When one franchise faces pressure, growth elsewhere can offset the drag.